C-XLI9FibroBiologics
fibroblast cell therapy, regenerative medicine, immune modulation
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-XLI9
C-XLI9C-XLI9fibroblast cell therapy, regenerative medicine, immune modulation
0-100 chain-logic scale · 15 dimensions · scored on public evidence
FibroBiologics states that fibroblast cell technology can reduce barriers to care and improve patients' lives by offering regenerative therapeutics for chronic disease. The company presents itself as the first biotech company using fibroblast cell technologies in regenerative medicine to cure chronic diseases, and it argues that fibroblast cells are more practical and effective than stem cells because they are easier to harvest, stronger, more effective, and have higher anti-inflammatory properties, making treatment more accessible and less expensive.
SourceFibroBiologics states a belief that fibroblasts, which it describes as the most common cell type in the body and a key connective-tissue cell, may have the power to treat or cure some of the most common chronic diseases through regenerative medicine.
SourceFibroBiologics presents the view that fibroblasts, described as one of only two human cell types able to regenerate tissue and organs, can be harnessed in cell-based therapies to treat or potentially cure common chronic diseases. The company states that its pre-clinical and limited clinical data for autoimmune disease are promising and says it is exploring fibroblasts as a way to improve and extend the productive life of aging organs such as the thymus.
Source